Targeting PVR (CD155) and its receptors in anti-tumor therapy

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Poliovirus receptor (PVR, CD155) has significant roles in both endogenous and immune functions.
• PVR is overexpressed in various human malignancies, suggesting a protumorigenic role.
• PVR interacts with immune cell receptors, modulating immune responses within the tumor microenvironment.

Purpose of the Study:

• To explore the therapeutic potential of targeting Poliovirus receptor (PVR, CD155) in cancer treatment.
• To investigate the role of PVR in tumor immunology and its implications for immunotherapy.
• To examine PVR's involvement in recombinant oncolytic virotherapy.

Main Methods:

• Review of scientific literature on PVR's function in cancer and immunology.
• Analysis of PVR expression patterns in healthy tissues versus malignancies.
• Examination of PVR's interactions with immune cell receptors and their functional consequences.

Main Results:

• PVR exhibits protumorigenic properties and is a target of interest in oncolytic virotherapy.
• PVR interactions with immune receptors are altered in the tumor microenvironment, promoting immunosuppression.
• Targeting PVR-mediated immune interactions is a promising strategy for cancer immunotherapy.

Conclusions:

• PVR is a significant therapeutic target in tumor immunology.
• Strategies targeting PVR interactions hold promise for checkpoint therapy and adoptive cell therapy.
• Further research into PVR's role can advance cancer treatment modalities.